Avivagen Announces Significant Order of OxC-betaTM in Brazil

Ottawa, ON /Business Wire/ August 3, 2022 /– Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce it has secured a significant order […]

Avivagen Announces Sales of Companion Animal Product and Management Change

AvivagenLogo

6,000 pouches ordered via new and existing customers in Taiwan and Mexico Chris Boland departs role as Chief Financial Officer Ottawa, ON /Business Wire/ July 29, 2022 /- Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake […]

Avivagen Inc. Announces Closing Of Third Tranche Of A Private Placement Of Shares And Warrants

Ottawa, ON / Business Wire/ July 6, 2022 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it has closed the third tranche (the […]

Avivagen Inc. Announces Options Grant

Ottawa, ON /Business Wire/ June 20, 2022/ Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance,  announces that its Board of Directors has approved the issuance of […]

Avivagen Announces Successful Completion of Formal Safety and Toxicology Evaluation of Fully Oxidized Beta-Carotene (OxBC)

Ottawa, ON /Business Wire/ June 9, 2022 /- Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that it has completed a series […]

Avivagen Provides Second Update on Non-Brokered Private Placement

Ottawa, ON / Business Wire/ June 3, 2022 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”) announces that the TSX Venture Exchange has granted a second extension of up to 30 days for completion of the balance of the Company’s previously announced non-brokered private placement of up to $5,000,000 (the “Offering”) through the issuance of […]

Closing of Second Tranche of Private Placement of Shares And Warrants for Proceeds of up to $5m

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Ottawa, ON / Business Wire/ May 31, 2022 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune […]

Avivagen Signs New Distribution Partner in Vietnam to Support Southeast Asian Growth

Ottawa, ON /Business Wire/ May 30, 2022 /- Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that it has signed a new […]

Avivagen Announces Approval in China, the World’s Largest Commercial Feed Production Market

Ottawa, ON /Business Wire/ May 12, 2022 /– Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that Avivagen’s oxidized carotenoid-based feed additive […]

Avivagen Provides Update on Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Ottawa, ON / Business Wire/ May 6, 2022 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”) announces that the TSX Venture Exchange has granted an extension of up to 30 days for completion of the balance of the Company’s […]